This prospective clinical trial aims to evaluate the efficiency, safety, and reliability of a minimally invasive graftless transcrestal sinus lifting approach with simultaneous dental implant placement in patients with edentulous posterior maxilla and limited residual bone height.

The study investigates bone formation beneath the Schneiderian membrane, implant stability, osseointegration, and long-term implant survival.

This prospective clinical study evaluates a minimally invasive graftless sinus lifting technique using a transcrestal approach with simultaneous implant placement in the posterior maxilla.

The procedure involves tenting the Schneiderian membrane without the use of grafting material, relying on blood clot formation and natural bone regeneration beneath the elevated membrane.

Radiographic and clinical evaluations will be performed preoperatively, immediately postoperatively, and at 6 months to assess bone formation, implant stability, and osseointegration.

Inclusion Criteria:

1. Adults aged 18-80 years.
2. Patients with edentulous posterior maxilla.
3. Residual bone height approximately 4-6 mm.
4. Indicated for transcrestal sinus membrane elevation.
5. Good general health (ASA I or II).
6. Ability to provide written informed consent.
7. Willingness to attend follow-up visits.

Exclusion Criteria:

1. Severe systemic diseases (ASA III or above).
2. Uncontrolled diabetes mellitus.
3. Active sinus pathology.
4. History of radiotherapy in the head and neck region.
5. Heavy smokers (>10 cigarettes/day).
6. Pregnancy or lactation.
7. Untreated periodontal disease.

7. Poor oral hygiene.

De-identified individual participant data (IPD) underlying the results reported in this study will be shared after publication. Data will be available upon reasonable request to the corresponding author. Requests must include a methodologically sound proposal and will require approval by the institutional review board. Data will be shared for academic purposes only.

De-identified individual participant data (IPD) and supporting documents will be made available beginning 6 months after publication of the primary results and will remain available for up to 5 years.

Access will be granted to qualified researchers who provide a methodologically sound research proposal. Requests will be reviewed by the principal investigator. Data will be shared after approval and signing of a data use agreement to ensure participant confidentiality.

This is an open-label single-arm prospective clinical study. No masking will be applied to participants, care providers, investigators, or outcome assessors.